Treatment modalities for narcolepsy

  title={Treatment modalities for narcolepsy},
  author={June M. Fry},
  pages={S43 - S48}
  • J. Fry
  • Published 1 February 1998
  • Psychology, Medicine
  • Neurology
Narcolepsy, a lifelong disorder, requires long-term management of symptoms. Interventions may be nonpharmacologic, such as lifestyle changes, and pharmacologic for relief of daytime sleepiness. Pharmacologic treatment of narcolepsy has depended on the use of CNS stimulants to increase wakefulness, vigilance, and performance. The medications considered effective in the treatment of narcolepsy include dextroamphetamine, pemoline, methylphenidate, methamphetamine, and modafinil; only… 

Figures from this paper

Management of Narcolepsy

Modafinil provides a useful alternative to traditional stimulants for the treatment of excessive daytime sleepiness associated with narcolepsy and shows long term efficacy without development of tolerance.

Treatment of Hypersomnia

Narcolepsy in Children

The current evidence supports the hypothesis that transmission of narcolepsy is multifactorial, with at least two genes, one of which is non-HLA related.

Chapter 13 Narcolepsy

Narcolepsy in the Older Adult

The discovery that narcolepsy/cataplexy results from the absence of neuroexcitatory properties of the hypothalamic hypocretin-peptidergic system will significantly advance understanding and treatment of the symptom complex in the future.

Pharmacological management of narcolepsy

This review addresses the state-of-the-art knowledge about the pharmacological treatment of narcolepsy along with the personal view of the authors.

Pharmacotherapy for excessive daytime sleepiness.

Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials

Although enerisant has a favorable pharmacokinetic profile, it is thought to have large interindividual variabilities in terms of efficacy and safety, suggesting the necessity of tailored dosage adjustments.

Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG

These findings demonstrate that the alertness-promoting effects of modafinil and d-amphetamine involve distinct EEG activities and do not reside on the same vigilance regulatory processes.

Narcolepsy:Clinical Features, New Pathophysiologic Insights, and Future Perspectives

The authors review the current state of knowledge onhypocretin anatomy, physiology, and function with special emphasis on theresearch regarding the hypocretin deficiency in narcolepsy, which may also explain associated features of the disorder, such as obesity.



Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy

  • Fry
  • Psychology, Medicine
    Annals of neurology
  • 1998
Modafinil demonstrated an excellent safety profile for up to 40 weeks of open‐label treatment and efficacy was maintained, suggesting that tolerance will not develop with long‐term use.

Treatment of narcolepsy with methamphetamine.

It is concluded that methamphetamine caused a dose-dependent decrease in daytime sleep tendency and improvement in performance in both narcoleptics and controls.


This study describes the clinical features, natural history and treatment of 100 patients with narcolepsy, with a minority of patients having muscle aches and jerks before sleep, double vision or loss of focus during cataplexy, went sleep‐walking by day, and had daytime hallucinations.

Differential effects of a new central adrenergic agonist--modafinil--and D-amphetamine on sleep and early morning behaviour in young healthy volunteers.

Modafinil (CRL 40476) is a recently developed central alpha adrenergic agonist with vigilance-promoting properties. In a double-blind, placebo-controlled sleep laboratory study, its single-dose

Modafinil in diurnal sleepiness. A study of 123 patients.

The efficacy of modafinil, a psychostimulant drug acting on postsynaptic alpha-1 adrenergic receptors, as a treatment for excessive daytime sleepiness was studied in 123 patients and the incidence of side effects was rather low.

Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness.

The multiple sleep latency test (MSLT) is used in the assessment and diagnosis of disorders of excessive somnolence and to evaluate daytime sleepiness in relation to various therapeutic or

Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil

Modafinil binds to the dopamine uptake carrier site with low affinity.

The results suggest a nonadrenergic mode of action in modafinil, and experiments in narcoleptic canines have shown that the compound does not modify canine cataplexy even at doses promoting alertness.

Maintenance of wakefulness test and multiple sleep latency test. Measurement of different abilities in patients with sleep disorders.

The data demonstrate that patients with diagnosable disorders of excessive somnolence may be discordant on the two tests and that the MWT may be a useful adjuvant daytime test in many clinical situations.